Their experiments using NEPC transgenic mouse models demonstrated that treatment with the Wee1 inhibitor AZD1775 and CHK1 inhibitor SRA737 effectively inhibited tumor growth, providing a promising approach for NEPC treatment [139]. The gene discussed is CHEK1; the disease is neoplasm.